New service supports big pharma’s drive to outsourcing by offering highly sophisticated technologies for drug discovery chemistry with leading computer-aided drug design services.
Lycera Corporation, a biopharmaceutical company pioneering innovative approaches to developing novel oral medicines to treat autoimmune diseases, announced that it has entered into an exclusive research collaboration with Merck to discover, develop and commercialize small molecules that target T-helper 17 (Th17) cells, key mediators of inflammation. The collaboration will focus on developing drug candidates that have the potential to treat major autoimmune diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and multiple sclerosis.
Scientists working at the European Molecular Biology Laboratory in Grenoble, France have developed a new technique that enables them to introduce up to 15 fluorescent markers to a mammalian cell in one go. They say their findings could help speed up drug development and screening.